Recent Updates
Recently added Catalysts
HUMA Negative Sentiment

HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm

Key Takeaway: A class action lawsuit has been filed against Humacyte, Inc. in the U.S. District Court for the Middle District of North Carolina. The lawsuit alleges that the company made materially false statements and failed to disclose significant operational deficiencies related to its Durham facility. These deficiencies include non-compliance with good manufacturing practices, which may affect the FDA's review of its application for ATEV for vascular trauma. Investors are encouraged to contact the law firm Bragar Eagel & Squire for more details, as the complaint outlines risks to the company's prospects and investor interests.
Price reaction · baseline $5.29 (2024-12-26 close) · hit after-hours · 1 other HUMA headline(s) in the window, move may be shared
day 0 close · peak
+4%

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Humacyte, indicating investor concerns.
  • Allegations of materially false and misleading statements by the company's executives.
  • Non-compliance with good manufacturing practices at the Durham facility could impact FDA approval.
  • Potential delays in FDA review of Humacyte's BLA due to remediation of deficiencies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+21%
120-day peak, hindsight
Typical move
7.2%
average across 3 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
Acellular Tissue Engineered Vessel
Phase 3 · Vascular Trauma

Full Press Release Details

NEW YORK, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) in the United States District Court for the Middle District of North Carolina on behalf of all persons and entities who purchased or otherwise acquired Humacyte securities between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”). Investors have until January 17, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose to investors: (1) that the Company's Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing; (2) that the FDA's review of the BLA would be delayed while Humacyte remediated these deficiencies; and (3) that, as a result, there was a substantial risk to FDA approval of ATEV for vascular trauma; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you purchased or otherwise acquired Humacyte shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

What is the class action lawsuit against Humacyte about?

The lawsuit claims Humacyte misled investors by failing to disclose manufacturing compliance issues.

What are the key dates for the Humacyte class period?

The class period for the Humacyte lawsuit runs from May 10, 2024, to October 17, 2024.

How can I join the class action for Humacyte?

Investors can apply to be lead plaintiff until January 17, 2025, via the court.

What risks did the lawsuit claim regarding FDA approval?

It claimed there was substantial risk to FDA approval of ATEV due to undisclosed deficiencies.

Who can I contact for more information on the lawsuit?

Contact Brandon Walker or Marion Passmore at investigations@bespc.com for more details.

Last updated: Dec 27, 2024